Navigation Links
Evelo Therapeutics Expands To New Headquarters In Cambridge
Date:12/17/2015

CAMBRIDGE, Mass., Dec. 17, 2015 /PRNewswire/ -- Evelo Therapeutics, a biotech company pioneering the development of microbiome-based therapies for cancer, today announces the official opening of its new 9,000-square-foot headquarters in Cambridge, Massachusetts. The company emerged from Flagship VentureLabs®, the innovation foundry of Flagship Ventures, with an initial capital commitment of $35 million in November 2015. The ribbon-cutting ceremony will be held today at 4 p.m. in collaboration with the Massachusetts Life Sciences Center (MLSC) and MassBio.

"I congratulate Evelo Therapeutics on their expansion and look forward to their continued contributions to job creation and innovation here in the Commonwealth," said Governor Charlie Baker.

"We are extremely pleased with our new facility and the opportunity that it affords Evelo during this important growth period," said Simba Gill, Ph.D., CEO of Evelo. "Cambridge is the undisputed hub of great biotech companies and we are excited to contribute to its legacy of innovative science and transformative medicine."

The new facility features state-of-the-art laboratory space and offices designed to foster collaboration. At this site, Evelo will continue to advance its research platform, based on a deep understanding of the cancer microbiome, and develop its Oncobiotic™ therapeutics as a new modality in cancer treatment.

"We are pleased to celebrate the grand opening of Evelo's new headquarters in Cambridge," said Travis McCready, President and CEO of the MLSC. "This new facility will allow the company to continue to grow and make important contributions to cancer therapeutics, one of the core strengths of our Commonwealth's life sciences ecosystem."

"We congratulate MassBio member Evelo Therapeutics on the grand opening of their exciting new headquarters in Cambridge, MA," said Robert K. Coughlin, President & CEO of MassBio. "We are thrilled to see Evelo Therapeutics' growth and know they will continue to thrive in Massachusetts' robust oncology research and development community."

Evelo Therapeutics is located at 620 Memorial Drive, Suite 200 West, Cambridge, MA 02139.

About Evelo Therapeutics
Evelo Therapeutics is dedicated to transforming cancer therapy through a deep understanding of the cancer microbiome. Evelo is discovering and developing Oncobiotic™ therapies, novel treatments designed to attack cancer by disrupting the microbial environment that supports tumors and protects them from the body's immune system. Evelo's platform disrupts the tumor microenvironment at the metabolic and stromal levels and provides next-generation, microbiome-based immunotherapeutics. Founded at Flagship VentureLabs, Evelo is the first microbiome company focused on cancer. For more information, please visit www.evelotx.com.

About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences.  For more information, visit www.masslifesciences.com.

About Flagship VentureLabs®
Flagship VentureLabs is the innovation foundry of Flagship Ventures. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs has used its unique, systematic approach to produce first-in-class companies based on in-house innovations. Since its founding in 2000, the VentureLabs team has founded more than 35 life science companies, including Joule Unlimited, Seres Therapeutics (NASDAQ: MCRB), Pronutria Biosciences, Symbiota and Moderna Therapeutics. For more information, please visit www.flagshipventures.com/venturelabs.

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release

Logo - http://photos.prnewswire.com/prnh/20151216/296703LOGO


'/>"/>
SOURCE Evelo Therapeutics
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Lyncean Technologies, Inc. receives $1.1M grant from DOE to develop the Compact Light Source
2. NSBRI Funds Cerebrotech to Accelerate Development of Brain Monitoring Device
3. Philanthropist John Moores Gives $2 Million to The Scripps Research Institute to Develop River Blindness Field Test
4. Algae.Tec Signs MOU with WorleyParsons for Global Project Development Program
5. Rockingham County Economic Development Launches New Website
6. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
7. ACM, Infosys Foundation Honor Google Developers for Transforming Internet-Scale Computing
8. NuView Life Sciences and Thomas Jefferson University Sign Agreement for Exclusive Development and Commercialization Rights to Novel Prostate Cancer Diagnostic
9. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
10. Aratana Therapeutics Adds To Drug Development Team
11. Brian Cousins Joins Opedix Joint Support Athletic Wear as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding into ... a broad range of contract analysis services for advanced applications. Services will ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):